skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Result Number Material Type Add to My Shelf Action Record Details and Options
1
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma

Rischin, Danny ; Hughes, Brett G M ; Basset-Séguin, Nicole ; Schadendorf, Dirk ; Bowyer, Samantha ; Trabelsi Messai, Sabiha ; Meier, Friedegund ; Eigentler, Thomas K ; Casado Echarren, Victoria ; Stein, Brian ; Beylot-Barry, Marie ; Dalac, Sophie ; Dréno, Brigitte ; Migden, Michael R ; Hauschild, Axel ; Schmults, Chrysalyne D ; Lim, Annette M ; Yoo, Suk-Young ; Paccaly, Anne J ; Papachristos, Apostolos ; Nguyen, Jenny-Hoa ; Okoye, Emmanuel ; Seebach, Frank ; Booth, Jocelyn ; Lowy, Israel ; Fury, Matthew G ; Guminski, Alexander

Journal for immunotherapy of cancer, 2024-03, Vol.12 (3), p.e008325 [Periódico revisado por pares]

England: BMJ Publishing Group Ltd

Texto completo disponível

Citações Citado por
2
535 A phase I/II study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors
535 A phase I/II study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors
Material Type:
Artigo 		Adicionar ao Meu Espaço

535 A phase I/II study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors

Lakhani, Nehal ; Johnson, Melissa ; Groisberg, Roman ; Han, Hyunsil ; Casey, Kerry ; Li, Siyu ; Skokos, Dimitris ; Seebach, Frank ; Lowy, Israel ; Fury, Matthew ; Mathias, Melissa

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A565-A565 [Periódico revisado por pares]

London: BMJ Publishing Group Ltd

Texto completo disponível

Citações Citado por
3
A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer
A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer

Kelly, William Kevin ; Hussain, Arif ; Saraiya, Biren ; Thanigaimani, Pradeep ; Sun, Furong ; Seebach, Frank A. ; Lowy, Israel ; Sandigursky, Sabina ; Miller, Elizabeth

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS284-TPS284 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
4
A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer
A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer

Kelly, William Kevin ; Thanigaimani, Pradeep ; Sun, Furong ; Seebach, Frank A. ; Lowy, Israel ; Sandigursky, Sabina ; Miller, Elizabeth

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS5105-TPS5105 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
5
A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: Trial-in-progress update
A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: Trial-in-progress update
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: Trial-in-progress update

Segal, Neil Howard ; Pelster, Meredith ; Girda, Eugenia ; Fong, Lawrence ; Olszanski, Anthony J. ; Han, Hyunsil ; Casey, Kerry A. ; Li, Siyu ; Welf, Erik ; Chen, Chieh-I ; Skokos, Dimitris ; Seebach, Frank A. ; Lowy, Israel ; Fury, Matthew G. ; Mathias, Melissa Divya ; Lakhani, Nehal J.

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS277-TPS277 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
6
A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC
A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC

Drilon, Alexander E. ; Awad, Mark M. ; Gadgeel, Shirish M. ; Villaruz, Liza C ; Sabari, Joshua K. ; Perez, Javier ; Daly, Christopher ; Patel, Shraddha ; Li, Siyu ; Seebach, Frank A. ; Lowy, Israel ; Magnan, Heather D. ; Rietschel, Petra

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS8593-TPS8593 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
7
A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti–PD-1) in patients with metastatic castration-resistant prostate cancer
A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti–PD-1) in patients with metastatic castration-resistant prostate cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti–PD-1) in patients with metastatic castration-resistant prostate cancer

Zhang, Jingsong ; Stein, Mark N. ; Kelly, William Kevin ; Tsao, Che-Kai ; Falchook, Gerald Steven ; Xu, Yuanfang ; Seebach, Frank A. ; Lowy, Israel ; Mohan, Kosalai Kal ; Kroog, Glenn ; Miller, Elizabeth

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.TPS174-TPS174 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
8
428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)
428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)
Material Type:
Artigo 		Adicionar ao Meu Espaço

428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)

Lewis, Karl ; Peris, Ketty ; Sekulic, Aleksandar ; Stratigos, Alexander ; Dunn, Lara ; Eroglu, Zeynep ; Chang, Anne Lynn ; Migden, Michael ; Li, Siyu ; Mohan, Kosalai ; Coates, Ebony ; Okoye, Emmanuel ; Baurain, Jean-François ; Bechter, Oliver ; Hauschild, Axel ; Butler, Marcus ; Hernandez-Aya, Leonel ; Licitra, Lisa ; Neves, Rogerio ; Ruiz, Emily ; Seebach, Frank ; Weinreich, David ; Yancopoulos, George ; Lowy, Israel ; Bowler, Timothy ; Fury, Matthew

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A260-A261 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
9
A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer
A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer

Drake, Charles G. ; Zhang, Jingsong ; Stein, Mark N. ; Xu, Yuanfang ; Seebach, Frank A. ; Lowy, Israel ; Mohan, Kosalai Kal ; Kroog, Glenn ; Miller, Elizabeth

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS5592-TPS5592 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
10
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Sezer, Ahmet ; Kilickap, Saadettin ; Gümüş, Mahmut ; Bondarenko, Igor ; Özgüroğlu, Mustafa ; Gogishvili, Miranda ; Turk, Haci M ; Cicin, Irfan ; Bentsion, Dmitry ; Gladkov, Oleg ; Clingan, Philip ; Sriuranpong, Virote ; Rizvi, Naiyer ; Gao, Bo ; Li, Siyu ; Lee, Sue ; McGuire, Kristina ; Chen, Chieh-I ; Makharadze, Tamta ; Paydas, Semra ; Nechaeva, Marina ; Seebach, Frank ; Weinreich, David M ; Yancopoulos, George D ; Gullo, Giuseppe ; Lowy, Israel ; Rietschel, Petra

The Lancet (British edition), 2021-02, Vol.397 (10274), p.592-604 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (1.317)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (1.377)
  2. Book Chapters  (54)
  3. magazinearticle  (24)
  4. Verbetes  (12)
  5. Newsletter Articles  (9)
  6. Resenhas  (6)
  7. Anais de Congresso  (3)
  8. Livros  (2)
  9. Artigos de Jornal  (2)
  10. Dissertações  (1)
  11. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de1975  (22)
  2. 1975Até1986  (78)
  3. 1987Até1998  (190)
  4. 1999Até2011  (560)
  5. Após 2011  (649)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (1.398)
  2. Japonês  (227)
  3. Alemão  (100)
  4. Português  (8)
  5. Francês  (7)
  6. Espanhol  (3)
  7. Polonês  (1)
  8. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.